Mylan Launches Remdesivir Under the Brand Name Desrem for COVID-19 in India
- Mylan launches Desrem (remdesivir) addressing the unmet needs amid COVID-19. The drug is approved for the treatment of suspected or laboratory-confirmed incidences of COVID-19 in adults and children hospitalized with severe symptoms
- Mylan will manufacture Desrem in its state-of-the-art injectable facility in Bangalore- India- and other export markets where Mylan has received a license from Gilead for the commercialization of remdesivir
- The company has released the first batch of its generic remdesivir and will continue to increase its supply across the country in the wake of the rising demand for the drug. Patients and HCPs can access information about the availability of Desrem in India through Mylan’s 24/7 national helpline number- +91.78299.80066
Ref: Mylan | Image: Ommcom News
Related News: Mylan’s Remdesivir Lyophilized Powder for Injection Receives the DCGI Accelerated Approval for Restricted Emergency Use in COVID-19 Patients in India
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].